IRON Price Prediction Next Week
Analysis and Insights
To predict the stock price of IRON for the next trading week, we analyze both technical indicators and news sentiment.
Technical Analysis:
The stock closed at $53.7 on 2025-03-24, with a volume of 331,397. The pre-market showed a +1.21% change, and the regular market had a +2.79% change. The latest real-time price is $53.62.
The RSI_14 is 48.34, near oversold territory, while the MACD is slightly negative at -0.78, indicating bearish momentum. The Stochastic Oscillator is at 37.47 for %K and 38.59 for %D, suggesting undervaluation.
Fibonacci levels show a pivot at 53.23, with resistance at 55.41 and 56.76, and support at 51.05 and 49.70. The stock is near the lower end of its recent range.
News Sentiment:
Insider sales have occurred, with Mona Ashiya selling shares twice and the CEO selling over 5,500 shares, indicating negative sentiment. However, institutional investors have increased their positions, with 82 adding shares and 67 reducing, showing mixed sentiment.
Analysts maintain a Buy rating with a median price target of $89, indicating bullishness despite insider activity.
Conclusion:
The stock may experience volatility but could find support around Fibonacci levels. Expect a slight dip to $52.50 before recovering to $54.20. Buy if the stock approaches lower Fibonacci support levels for a favorable risk/reward ratio.
Target Price: $54.20
Recommendation: Buy if the stock approaches support levels.
IRON Similar Chart Price Prediction
The price of IRON is predicted to go up 5.67%, based on the high correlation periods with CNTY. The similarity of these two price pattern on the periods is 91.39%.
IRON
CNTY
Up: 5.67%Similarity: 91.39%
IRON Revenue Forecast
IRON EPS Forecast
IRON FAQs
What is IRON eps forecast for next quarter？
IRON Analyst's Forecast
Kristen Kluska
Cantor Fitzgerald
Buy
2025-03-18
Price Target
$99 → $132
Upside
+149.86%
Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Disc Medicine to $132 from $99 and keeps an Overweight rating on the shares. Disc Medicine plans to file a new drug application for oral GlyT1 inhibitor, bitopertin in erythropoietic protoporphyria and X-linked protoporphyria, rare heme diseases where patients experience debilitating pain when exposed to sunlight/ artificial light, in the second half of 2025, the analyst tells investors in a research note. The firm sees peak sales of $900M in the U.S. in 2035, up from its previous estimate of $430M.
Jeffrey Hung
Morgan Stanley
Buy
2025-03-07
Price Target
$85
Upside
+52.69%
Greg Harrison
Scotiabank
Buy
2025-03-03
Price Target
$73 → $75
Upside
+38.07%
